Discovering Cancer Risks Through Innovative Micro CTC Test from Shibuya

Micro CTC Test Revolutionizes Cancer Risk Detection

In a significant advancement in cancer diagnostics, the Micro CTC test, developed by CellCloud, has been selected as a thank-you gift for Hometown Tax donations in Shibuya, Tokyo. This innovative cancer risk assessment will be available for donations starting June 12, 2025. Unlike traditional tests, the Micro CTC requires only a single 5-minute blood draw to effectively capture circulating tumor cells (CTCs) in the bloodstream, providing a comprehensive risk analysis for various cancers, excluding blood cancers.

CellCloud, headquartered in Shibuya, is leading the way in cancer risk assessments with its state-of-the-art testing center, ensuring rapid and precise results. This groundbreaking test has garnered immense recognition for its efficiency and clarity, enabling patients to understand their cancer risk more effectively by quantifying the exact number of cancer cells present in their blood.

Thanks to the rigorous evaluations conducted by the Ministry of Internal Affairs and Communications and Shibuya City, the Micro CTC test has earned its status as a reliable option, aiming to promote wider utilization of this advanced cancer risk assessment. The incorporation of the test as a thank-you gift underscores the commitment to enhancing community health and providing citizens with accessible tools for early cancer detection.

The Micro CTC test operates on the principle of detecting CTCs — circulating tumor cells released into the bloodstream from tumors. Such tests have been significantly advanced abroad, with over 35,000 research papers published in Europe and the United States. The FDA, which functions similarly to Japan’s Ministry of Health, Labour and Welfare, has also acknowledged the importance of these assessments in the fight against cancer.

CellCloud’s Micro CTC test stands out by enhancing the quality and precision of existing CTC testing methods. With a focus on identifying high-grade cancer cells exhibiting epithelial-mesenchymal transition (EMT) — cells known for their invasive and metastatic capabilities — the test utilizes a CSV (cell surface vimentin) antibody, achieving a specificity rate of 94.45%. This level of accuracy is essential in determining cancer risk, making the test not only reliable but also safe and straightforward for patients compared to traditional methods.

Through its collaboration with local clinics, including the Yoyogi Clinic in Shibuya, CellCloud has already facilitated numerous screenings, receiving positive feedback from patients who appreciate the swift and non-invasive nature of the Micro CTC test. The company’s overarching mission is to eliminate the fear and suffering associated with cancer, striving to ensure that as many individuals as possible can benefit from this revolutionary test.

As a part of its initiative, CellCloud emphasizes the importance of accessible cancer screening services as a way to foster community support and involvement. The expansion and promotion of the Micro CTC test will not only contribute to individual health but also strengthen community ties through collaborative health initiatives.

Details on the Thank-You Gift

Target: One-time use Micro CTC cancer risk assessment for individuals.
For further details and to apply, please visit Shibuya’s Hometown Tax page or private donation service sites.

Visit Shibuya's Hometown Tax Page